InterMune Presents Top-line Results from Phase 1b Trial of HCV Protease Inhibitor ITMN-191 Monotherapy <a href="http://www.hivandhepatitis.com/hep_c/news/2008/040408_a.html" target="_blank">http://www.hivandhepatitis.com/hep_c/news/2008/040408_a.html</a>